- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Nivolumab Plus Chemotherapy Shows Potential as New SOC in Gastric and GEJ Cancers
March 05, 2021
In an interview with Targeted Oncology, Markus Moehler, MD, PhD, reviewed the potentially practice-changing data from the phase 3 CheckMate 649 clinical trial.
Study of CRX100 Makes Progress in Patients With Refractory Solid Tumors
March 05, 2021
The novel combined immunotherapy CRX100 has been dosed in the first patient with refractory solid tumors in a phase 1, open-label, dose-escalation study.
Brentuximab Vedotin Plus Chemotherapy Works as a Primary Option for Hodgkin Lymphoma
March 05, 2021
Pierluigi Porcu, MD, explained how the combination of brentuximab vedotin plus chemotherapy works in in frontline setting of Hodgkin lymphoma during a virtual Targeted Oncology Case-Based Roundtable event.
Doctors Debate: Is Systemic or Liver-Directed Therapy Best for Hepatocellular Carcinoma?
March 05, 2021
As part of the virtual 17th Annual Meeting of the International School of Gastrointestinal Oncology, a debate ensued around whether liver-directed or systemic therapy is best for the treatment of patients with HCC.
Cavrotolimod Granted Orphan Drug Designation for Merkel Cell Carcinoma
March 05, 2021
The FDA granted Orphan Drug Designation to cavrotolimod, for the treatment of patients with Merkel cell carcinoma, announced Exicure, Inc, in a press release.
Toripalimab Rolling Submission of BLA Initiated for Nasopharyngeal Carcinoma
March 04, 2021
A rolling submission of the Biologics License Application was initiated for toripalimab for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma.
FDA Grants Priority Review to Injectable Pafolacianine Sodium to Identify Ovarian Cancer During Surgery
March 04, 2021
The FDA has accepted a New Drug Application for pafolacianine sodium injection and granted it Priority Review as a potential adjunct for identifying ovarian cancer during surgery.
Exploring When to Use Neoadjuvant Treatment in TNBC
March 04, 2021
Adam M. Brufsky, MD, PhD, discusses the use of neoadjuvant therapy for patients with triple–negative breast cancer.
FDA Approves Expanded Indication for Lorlatinib for Frontline ALK+ NSCLC
March 04, 2021
The FDA has expanded the approval for lorlatinib to include an indication for the first-line treatment of patients with ALK-positive non–small cell lung cancer.
Real-World Data to Inform Lung Treatment in the Future
March 03, 2021
Robert Coleman, MD, FACOG, FACS, discusses the research model he utilizes to bring more patient research to the lung cancer field, a topic he presented on during the Association of Community Cancer Centers Annual Meeting.
Blinatumomab Improves Survival Outcomes Over Chemotherapy in High-Risk B-ALL
March 03, 2021
Blinatumomab consolidation demonstrated significantly prolonged event-free survival in pediatric patients with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia when compared with chemotherapy before allogeneic hematopoietic stem cell transplantation.
KarMMa Data in Multiple Myeloma Published as FDA Considers Potential Ide-Cel Approval
March 03, 2021
Full results from the phase 2 KarMMa trial decabtagene vicleucel show the promise of idecabtagene vicleucel in relapsed and refractory multiple myeloma.